(Total Views: 553)
Posted On: 08/16/2025 10:09:40 PM
Post# of 155816
Re: craigakess #155781
In June the company announced the first patient dosed in a trial in well over 2 years. IMO that should be seen as absolutely monumental news.
Plus the March shareholders' letter was chock full of info on potentially pursuing 5 other indications along with a search for a partner in NASH.
Share price volatility is not surprising with any clinical-stage company but the cap has held up well and an S-3 likely telegraphing a financing usually asserts downward pressure.
Cytodyn has transformed into a typical small clinical-stage company, it's not the Nader carny show anymore, and most similar companies just release news when it happens along with intermittent general updates. I don't see how anybody can look at what's going on and not see that the company is making progress.
Maybe there will be a major partnership announced Monday, maybe it will take phase 2 data to generate real interest from big pharma, who knows, but it sure seems like Cytodyn has steadily started putting one foot in front of the other in the right direction.
Plus the March shareholders' letter was chock full of info on potentially pursuing 5 other indications along with a search for a partner in NASH.
Share price volatility is not surprising with any clinical-stage company but the cap has held up well and an S-3 likely telegraphing a financing usually asserts downward pressure.
Cytodyn has transformed into a typical small clinical-stage company, it's not the Nader carny show anymore, and most similar companies just release news when it happens along with intermittent general updates. I don't see how anybody can look at what's going on and not see that the company is making progress.
Maybe there will be a major partnership announced Monday, maybe it will take phase 2 data to generate real interest from big pharma, who knows, but it sure seems like Cytodyn has steadily started putting one foot in front of the other in the right direction.
(22)
(0)
